Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the hepatitis C virus drug market will expand dramatically from $2 billion in 2008 to nearly $7.7 billion in 2013 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. However, market growth thereafter will decrease to $3.4 billion in 2018 owing to a decline in the prevalence of the disease and the high efficacy of new treatment regimens.

The new Pharmacor report entitled Hepatitis C Virus finds that, through 2013, robust market growth will be driven by the launches of novel hepatitis C virus-specific agents and an increase in the size of the drug-treated population. Roche and Schering-Plough will continue to be prominent players and a number of other companies -- including Johnson & Johnson and Pfizer -- will also carve out a share in the market.

The report also finds that the competitive hepatitis C virus pipeline is characterized by its significant commercial potential which is well-recognized by drug developers. Several agents in late-stage development -- most notably protease inhibitors such as Vertex/Johnson & Johnson/Mitsubishi Tanabe's telaprevir and Schering-Plough's boceprevir as well as polymerase inhibitors such as Roche/Pharmasset's R-7128 and Pfizer's filibuvir -- will drive market growth.

"The standard of care will change significantly with the introduction of new classes of hepatitis C virus-specific antiviral agents, such as protease inhibitors and polymerase inhibitors," said Decision Resources Analyst Alexandra Makarova, M.D., Ph.D. "Compounds from these new classes will initially be added to the backbone of currently used agents, forming triple or quadruple treatment regimens that are expected to be more efficacious than the current standard of care."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Decision Resources                               Decision Resources, Inc.   Christopher Comfort                              Elizabeth Marshall   781-296-2597                                     781-296-2563   ccomfort@dresources.com                          emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort of Decision Resources, +1-781-296-2597,
ccomfort@dresources.com; or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimer's Disease Market

View Now